Review Services
Institutional Biosafety Committee (IBC) Services
Advarra’s IBC services provide rapid, flexible solutions for IBC reviews, especially critical for gene therapy and other high-stakes research. With proven experience, Advarra supports sites in achieving regulatory compliance in 10 business days or less, accelerating study startup and making sites more attractive to sponsors and CROs.
Key Features
- IBC review in ≤10 days
- Coordinated institutional review board (IRB)/IBC review
- Oncology gene therapy expertise
- Complimentary NIH registration support
- Year-round compliance management
Streamlined IBC Support for Accelerated Research
Rapid Review
Advarra consistently delivers IBC reviews within 10 business days, helping your study avoid delays and move forward quickly.
More Experience and Expertise
With more studies reviewed and more registered sites than any other provider, Advarra’s IBC has broader, more diverse experience for more knowledgeable reviews.
Tailored Biosafety Solutions
From IBC setup to ongoing monitoring, Advarra provides customized support based on your site’s specific needs and experience.
Coordinated Reviews
Simultaneous IBC and IRB reviews improve consistency and reduce the complexity and time involved in regulatory approvals.
Proven Efficiency
With a track record of handling high-volume submissions efficiently, Advarra reduces the burden on sites and accelerates study activation.
International Coverage
Leveraging a nationwide network of biosafety experts, Advarra can quickly support sites across the U.S. and beyond, ensuring timely reviews regardless of location.
Gene Therapy Expertise
Oncology Specialization
Specialized in oncology gene therapy trials, with dedicated panels that understand cutting-edge research and regulatory requirements.
Therapeutic Range
Deep experience across multiple therapeutic areas such as infectious diseases, vaccines, genetic disorders, regenerative medicine, and neurology.
Site-specific Solutions
Tailored guidance on setting up IBCs, staff training, and implementing biosafety protocols to meet the demands of gene therapy trials.
Proven Success
Expertise in managing accelerated timelines, with a track record of supporting complex gene therapy trials, including 100% of Operation Warp Speed COVID-19 vaccines.
